Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:41 AM
Ignite Modification Date:
2025-12-25 @ 4:41 AM
NCT ID:
NCT04213118
Eligibility Criteria:
Inclusion Criteria:
* Patients participate in the study voluntarily and sign informed consent with good compliance.
* After hepatectomy, satisfy any of the following recurrence factors was assessed:≥5 cm and \< 10 cm of tumor diameter; tumor number≥3; tumor microvascular invasion grade M1; portal vein carcinoma thrombus resection(Ⅰ、Ⅱ).
* Histological or cytological confirmation of hepatocellular carcinoma, or at least two imaging tests with hepatocellular carcinoma characteristics, or one imaging test with hepatocellular carcinoma characteristics and AFP \> 400μg/L.
* TACE treatment (cTACE only) was completed within 1-2 months after hepatectomy.
* ≥ 18 and ≤ 75 years of age.
* ECOG performance status of 0-1.
* liver function child-Pugh class A or B (≤7 points).
* Except for hepatectomy, no previous tumor-related treatment was received, and the remaining liver was assessed to have good liver function.
Exclusion Criteria:
* Patients who have had or are currently complicated with other malignant tumors,or recurrent hepatocellular carcinoma (\>10 mm)in baseline data or in TACE.
* Patients with absolute contraindications to TACE.
* Patients with HCV infection.
* Urine protein ≥ ++，and 24-hour urinary protein excretion\>1.0 g confirmed.
* Pregnant or lactating women.
* Patients with mental illness.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT04213118
Study Brief:
Protocol Section:
NCT04213118